Fate Therapeutics

FATENasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$326.366 M

$2.80 +12.45%

Close of 7 Aug 2026

Revenue

$6.65M

#3246 by revenue

Earnings

-$136.3M

Loss-making

Shares outstanding

116,559,186

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#82Palisade BioPALI$366.3M
#83Century TherapeuticsIPSC$360.7M
#84Fate TherapeuticsFATE$326.4M
#85Inhibikase TherapeuticsIKT$326.1M
#86AgenusAGEN$311.5M

Where these numbers come from

Share counts and financials for Fate Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.